Skip to content
Storytelling Co – Lifestyle
Author:
Nanobiotix S.A.
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
April 1, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
March 30, 2026
←
Previous Page
1
2
3